Aminopenicillins vs non-aminopenicillins for treatment of enterococcal lower urinary tract infections
Recommended Citation
de Oca JEM, Veve MP, Zervos MJ, and Kenney RM. Aminopenicillins versus Non-aminopenicillins for Treatment of Enterococcal Lower Urinary Tract Infections. Int J Antimicrob Agents 2023; 106800.
Document Type
Article
Publication Date
6-1-2023
Publication Title
International journal of antimicrobial agents
Abstract
Aminopenicillins achieve urinary concentrations that exceed typical minimum inhibitory concentrations for enterococcal lower urinary tract infection (UTI). Our clinical microbiology laboratory discontinued routine susceptibilities on enterococcal urine isolates and reports "aminopenicillins are predictably reliable for uncomplicated enterococcal UTI". The study objective was to compare outcomes of aminopenicillins (AP) to non-aminopenicillins (NAP) for enterococcal lower UTIs. This was an IRB approved, retrospective cohort of adults hospitalized with symptomatic enterococcal lower UTIs from 2013-2021. Primary endpoint: composite clinical success at 14-days, defined as resolution of symptoms without new symptoms and no repeat culture growth of index organism. A non-inferiority analysis was utilized with a 15% margin, and logistic regression evaluated characteristics associated with 14-day failure. 178 subjects were included: 89 AP, 89 NAP. VRE was identified in 73 (82%) AP and 76 (85%) NAP patients (P=0.54); a total of 34 (38.2%) AP and 66 (74.2%) NAP patients had confirmed E. faecium (P<0.001). Amoxicillin (36, 40.5%) and ampicillin (36, 40.5%) were the most frequent AP utilized; linezolid (41, 46%) and fosfomycin (30, 34%) were the most frequent NAP. 14-day clinical success for AP and NAP was 83.1% and 82.0% (1.1% difference, 97.5%CI, -0.117-0.139). Among the E. faecium subgroup, 14-day clinical success was observed in 27/34 (79.4%) of AP and 53/66 (80.3%) of NAP patients (P=0.916). In logistic regression, APs were not associated with 14-day clinical failure (adjOR 0.84; 95%CI, 0.38-1.86). Aminopenicillins were noninferior to non-aminopenicillins for treating enterococcal lower UTIs and may be considered irrespective of susceptibility results.
Medical Subject Headings
Adult; Humans; Anti-Bacterial Agents; Retrospective Studies; Gram-Positive Bacterial Infections; Enterococcus; Ampicillin; Urinary Tract Infections; Enterococcus faecium; Microbial Sensitivity Tests
PubMed ID
37004756
ePublication
ePub ahead of print
Volume
61
Issue
6
First Page
106800
Last Page
106800
